Program
Flu H5 egg pandemic low dose vaccine, with adjuvant
Also written as “Flu H5 Egg Pandemic medium dose vaccine, with adjuvant”, “Flu H5 Egg Pandemic high dose vaccine, with adjuvant” and “Flu H5 Egg Pandemic high dose vaccine, without adjuvant”.
Its studies are mostly in Influenza, Human, led by Sanofi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 11 open or running | phase 2since Jul 31, 2026 | Jul 31, 2026 | Feb 22, 2028phase 2 · NCT07779408 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 31, 2026First study: phase 2 study in Influenza, HumanFirst studyNCT07779408 · 640 planned · United States
Ahead
- Feb 22, 2028Primary completion: phase 2 study in Influenza, HumanNCT07779408
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Flu H5 egg pandemic low dose vaccine, with adjuvant”name, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07779408Influenza, Human · United States | 2 | Recruiting | Feb 22, 2028 | 640 |
How it is read
Names in the registry
- “Flu H5 egg pandemic low dose vaccine, with adjuvant”, 1 entry
- “Flu H5 Egg Pandemic medium dose vaccine, with adjuvant”, 1 entry
- “Flu H5 Egg Pandemic high dose vaccine, with adjuvant”, 1 entry
- “Flu H5 Egg Pandemic high dose vaccine, without adjuvant”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.